Skip to main content

Search

Reset all filters
257 Result(s)
Sort by

Nelli Milosch

Nelli Milosch

Nelli Milosch, a team lead for our field-based medical team in Germany, says that the people is the best thing about working in Boehringer Ingelheim.
Stefanie Bock Kreilinger

Stefanie Bock Kreilinger

Stefanie Bock-Kreilinger works in the legal department at Boehringer Ingelheim as head of corporate legal medicine, evidence and digital health.
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for chronic heart failure1 Heart failure represents a significant, growing disease burden
New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD

New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD

New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD
EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction
Business Ethics

Business Ethics

The ethical principles that have guided Boehringer Ingelheim for 130 years created a culture of corporate and social responsibility and commitment.
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis 

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis 

Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer